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CLINICAL SCIENCE
Incidence of Tuberculosis Among HIV-Positive Individuals
Initiating Antiretroviral Treatment at Higher CD4 Counts in
the HPTN 071 (PopART) Trial in South Africa
Peter Bock, MRCP, MPH,* Karen Jennings, MBChB,† Redwaan Vermaak, MA,*
Helen Cox, BSc, MPH, PhD,‡ Graeme Meintjes, FCP, PhD,‡§ Geoffrey Fatti, MBChB, MPH,k
James Kruger, MPH,¶ Virginia De Azevedo, MBChB,# Leonard Maschilla, Bsc,**
Francoise Louis, MBChB, DTM&H, DipHIVMan,k Colette Gunst, MBChB, FCFP,#**
Nelis Grobbelaar, MBChB,†† Rory Dunbar, Msc,* Mohammed Limbada, MBChB, Msc,‡‡
Sian Floyd, Msc,§§ Ashraf Grimwood, MBChB, MPH,k Helen Ayles, MRCP, PhD,kk
Richard Hayes, Dsc, FMedSci,§§ Sarah Fidler, FRCP, PhD,¶¶ and Nulda Beyers, FCP, PhD,* on behalf
of the HPTN 071, PopART team
Introduction: Antiretroviral treatment (ART) guidelines recom-
mend life-long ART for all HIV-positive individuals. This study
evaluated tuberculosis (TB) incidence on ART in a cohort of HIV-
positive individuals starting ART regardless of CD4 count in
a programmatic setting at 3 clinics included in the HPTN 071
(PopART) trial in South Africa.
Methods: A retrospective cohort analysis of HIV-positive individ-
uals aged $18 years starting ART, between January 2014 and
November 2015, was conducted. Follow-up was continued until 30
May 2016 or censored on the date of (1) incident TB, (2) loss to
follow-up from HIV care or death, or (3) elective transfer out;
whichever occurred ﬁrst.
Results: The study included 2423 individuals. Median baseline
CD4 count was 328 cells/mL (interquartile range 195–468); TB
incidence rate was 4.41/100 person-years (95% conﬁdence interval
[CI]: 3.62 to 5.39). The adjusted hazard ratio of incident TB was
0.27 (95% CI: 0.12 to 0.62) when comparing individuals with
baseline CD4 .500 and #500 cells/mL. Among individuals with
baseline CD4 count .500 cells/mL, there were no incident TB cases
in the ﬁrst 3 months of follow-up. Adjusted hazard of incident TB
was also higher among men (adjusted hazard ratio 2.16; 95% CI:
1.41 to 3.30).
Conclusions: TB incidence after ART initiation was signiﬁcantly
lower among individuals starting ART at CD4 counts above 500
cells/mL. Scale-up of ART, regardless of CD4 count, has the
potential to signiﬁcantly reduce TB incidence among HIV-positive
individuals. However, this needs to be combined with strengthening
of other TB prevention strategies that target both HIV-positive and
HIV-negative individuals.
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INTRODUCTION
Tuberculosis (TB) remains the leading cause of mor-
bidity and mortality among HIV-positive individuals.1 Recent
antiretroviral treatment (ART) World Health Organization
(WHO) guidelines recommend life-long ART for all HIV-
positive individuals regardless of CD4 count.2 This expanded
ART access should lead to a reduction of TB and other WHO-
deﬁning illnesses and mortality among HIV-positive individ-
uals initiating ART.3–6
TB at the time of ART initiation (baseline TB) is
signiﬁcantly higher at lower baseline CD4 counts among
HIV-positive individuals.4 Two South African programmatic
studies completed between 2002 and 2008, in patients with
low median baseline CD4 counts, reported high baseline TB
prevalence, between 20% and 30%,7,8 and baseline TB
prevalence continues to be underestimated because of the
difﬁculties in diagnosing among individuals starting ART in
routine settings.9
Published TB incidence rates (IRs) in the ﬁrst 12
months on ART range from 7.3/100 person-years (PY) to
10.9/100PY and are particularly high when pre-ART (base-
line) CD4 counts are below 100 cells/mL.8,10 TB IRs have
been reported to be highest during the ﬁrst 4 months on ART
and approximately double in the ﬁrst year of ART compared
with subsequent years.9 When measuring the association
between CD4 count measured after a period of immune
reconstitution on ART (“on ART” CD4 counts) and TB
incidence, TB incidence is signiﬁcantly lower among indi-
viduals with higher “on ART” CD4 counts.7,10
Although randomized controlled trials have shown
lower TB incidence among HIV-positive individuals initiat-
ing ART at baseline CD4 counts .500 cells/mL compared
with CD4 #500 cells/mL and CD4 351 to 500 cells/mL,11,12
there are very few published studies from programmatic
settings on the impact of routine ART initiation at CD4
counts .500 cells/mL on TB incidence. This study, embed-
ded in the HPTN 071 (PopART) trial, assessed the association
between baseline CD4 count and TB incidence after ART
initiation in a cohort of HIV-positive individuals starting ART
regardless of CD4 count under programmatic conditions in
the Western Cape, South Africa.
STUDY SETTING
The study was conducted at 3 primary health care
(PHC) Department Of Health (DOH) clinics that offered ART
regardless of CD4 count (arm A) for the “Population Effect of
ART to Reduce HIV Incidence,” HPTN 071 (PopART)
study. Study clinics were in 2 subdistricts in the Cape Metro
district (metro 1 and metro 2 clinics) and in 1 subdistrict in the
Cape Winelands district (Rural clinic). Antenatal HIV
prevalence in the Cape Metro and Cape Winelands districts
is 20.3% and 14.3%, respectively, and routine DOH data
show that annual TB IRs are 596/100,000 and 880/100,000
population, respectively.13,14
A full description of the HPTN 071 (PopART) study
design has been previously published.15 Communities ran-
domly allocated to arm A of the HPTN 071 (PopART) trial
received, from January 1, 2014, a combination HIV pre-
vention package including HIV education, HIV testing,
screening for TB symptoms, and active linkage to care for
individuals diagnosed with HIV, TB, and sexually transmitted
infections. Clinics allocated to arm A of the HPTN 071
(PopART) trial provided ART regardless of CD4 count to all
HIV-positive individuals aged $18 years. Clients initiating
ART outside prevailing ART guidelines signed research
informed consent before ART initiation. All HIV-positive
individuals on ART were otherwise managed according to
DOH ART guidelines. Routine assessment before ART
initiation included TB symptom and pregnancy screening.16
HIV and TB services were integrated at all 3 study
clinics. Isoniazid TB prophylaxis (IPT) was recommended for
individuals with a positive tuberculin skin test (TST) at ART
initiation, to be continued for 36 months. If TST was
unavailable or negative, then a 12-month IPT was advised
for individuals starting ART.16 HIV-positive individuals with
TB symptoms were investigated according to a standardized
diagnostic algorithm that used GeneXpert MTB/RIF (Xpert)
for ﬁrst-line diagnostic investigation, followed by culture if
Xpert was negative. HIV-positive individuals, diagnosed with
TB at ART initiation and started on TB treatment, were
recorded in the routine DOH electronic TB monitoring system
(ETR.net) and stabilized on TB treatment for 2 to 8 weeks
before ART initiation.17 The same TB diagnostic algorithm
was used for diagnosis of TB in individuals already initiated
on ART.18
COHORT OVERVIEW, DATA SOURCES,
AND DEFINITIONS
A retrospective cohort study design was used. All data
were obtained from routine DOH systems including the
routine HIV monitoring system, Tier.net,19 ETR.net, and
routine laboratory reports from the National Health Labora-
tory Services. All HIV-positive individuals aged $18 years,
recorded in Tier.net as having started ART at the 3 study
clinics between January 1, 2014 and November 30, 2015 with
a recorded baseline CD4 count, were included in the study
sample. Individuals were followed up until May 30, 2016 or
until the date of (1) incident TB, (2) loss to follow-up (LTFU)
from HIV care or death, or (3) elective transfer out (TFO);
whichever occurred ﬁrst.
Data linkage between Tier.net and ETR.net was con-
ducted using an automated linkage algorithm in Microsoft
SQL Server previously validated in other studies, which used
the ﬁrst name, surname, and date of birth as individual
identiﬁers, and linkages were validated manually. CD4 data
missing from Tier.net were, where available, extracted
directly from the National Health Laboratory Services
database and linked to Tier.net data using the DOH unique
identiﬁer. Data cleaning and validation included manual
checking of automated linkages and cross referencing data
of key across data elements within Tier.net and within ETR.
net.
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The following standardized deﬁnitions were used; (1)
baseline CD4 as the most recent CD4 count completed within
6 months before starting ART. Baseline CD4 categories were
chosen to align with previous guideline ART criteria,20 (2)
baseline TB as recorded in ETR.net as having started on TB
treatment in the 6 months before ART initiation, (3)
bacteriologically conﬁrmed TB as conﬁrmed with TB on
smear microscopy, Xpert, or culture on one of sputum, lymph
node tissue, pleural effusion, or cerebrospinal ﬂuid, (4)
incident TB as recorded in ETR.net as starting TB treatment
after ART initiation; this included individuals on TB
treatment at baseline who, after stopping TB treatment while
on ART, were subsequently recorded in ETR.net as restarting
TB treatment for a new TB episode, (5) LTFU as 3 months
late for an antiretroviral pharmacy pickup appointment. LTFU
was reported in combination with death because of signiﬁcant
underreporting of death in Tier.net, (6) TFO as electively
transferred to another health facility.
Baseline characteristics were described using standard
descriptive statistics for continuous and categorical variables.
Heterogeneity of baseline characteristics across baseline CD4
count categories was assessed using x2 and Kruskal–Wallis
tests. Binomial conﬁdence intervals (CIs) were generated for
baseline TB prevalence by baseline CD4 count category.
Person time was measured from ART initiation or from the
estimated date of stopping baseline TB treatment. Recording
of the outcome date of baseline TB episodes in ETR.net was
of poor quality; therefore, the outcome date for baseline TB
cases was assumed to be 6 months after the start of TB
treatment in all cases. The date for incident TB was the date
an individual started TB treatment recorded in ETR.net. In-
dividuals were permanently censored at the ﬁrst occurrence of
either incident TB, LTFU, TFO, or May 30, 2016.
Time-to-event analyses were completed using Kaplan–
Meier survival estimates. Cox regression was used for crude
and adjusted modeling of the association of baseline charac-
teristics with incident TB. Proportional hazard assumptions
were tested using Schoenfeld residuals. Baseline variables for
inclusion in regression analysis were selected a priori, based
on clinical signiﬁcance. Selection of the baseline variable
category used for comparison (hazard ratio [HR] = 1) was
based on sample size and clinical signiﬁcance. All adjusted
models included the following baseline characteristics unless
otherwise stated: baseline CD4 count, age, sex, pregnancy
status, baseline TB, previous ART exposure of more than 3
months, and clinic and year of ART initiation. Likelihood
ratios were used to calculate P values in regression models for
categorical independent variables with more than 2 strata. A
subset analysis was conducted excluding individuals with
baseline TB. A sensitivity analysis was also conducted in
which incident cases of TB were restricted to bacteriologi-
cally conﬁrmed cases. Logistic regression was used to com-
pare baseline characteristics of individuals retained in the
study sample and those combined LTFU and TFO. All
analyses were performed using Stata version 13 (StataCorp
LP, College Station, TX).
ETHICS STATEMENT
The HPTN 071 (PopART) study was approved by the
Stellenbosch University Health Research Ethics Committee
(SU HREC) (Ref. No. N12/11/074) and the London School
of Hygiene and Tropical Medicine research ethics com-
mittee (Ref no. 6326). All individuals starting ART outside
prevailing routine guidelines signed informed consent.
Further approvals for this study, including for the use of
TABLE 1. Baseline Characteristics of Study Cohort
Baseline CD4 Cell Count
(Cells/mL) 0–200 201–350 351–500 .500 All
P*N (%)† 631 (26.0) 708 (29.2) 582 (24.0) 502 (20.7) 2423
Sex Female N (%) 355 (56.3) 463 (65.4) 421 (72.3) 404 (80.5) 1643 (67.8) ,0.001
Male N (%) 276 (43.7) 245 (34.6) 161 (27.7) 98 (19.5) 780 (32.1)
Age (yr) Median (IQR) 33 (29.0–40.0) 31 (25.0–37.0) 31 (26.0–37.0) 30 (25.0–37.0) 31 (26.0–38.0) ,0.001
18–25 N (%) 79 (12.5) 179 (25.3) 142 (24.4) 134 (26.7) 534 (22.0) ,0.001
26–35 N 312 (49.6) 311 (43.9) 272 (46.7) 227 (45.2) 1122 (46.3)
36–45 N 167 (26.5) 138 (19.5) 109 (18.7) 87 (17.3) 501 (20.7)
46–55 N 57 (9.0) 63 (8.9) 46 (7.9) 44 (8.8) 210 (8.7)
.55 N 17 (2.7) 17 (2.4) 13 (2.2) 10 (2.0) 57 (2.3)
Pregnant at ART start Yes N 14 (3.9) 39 (8.4) 41 (9.7) 48 (11.9) 142 (8.6%) ,0.001
Baseline TB Yes N 162 (25.7) 56 (7.9) 41 (6.7) 26 (5.2) 285 (11.8) ,0.001
Clinic Rural clinic N 88 (13.9) 113 (15.9) 126 (21.7) 127 (25.3) 454 (18.7) ,0.001
Metro clinic 1 N 299 (47.4) 301 (42.5) 231 (39.7) 191 (38.1) 1022 (42.2)
Metro clinic 2 N 244 (38.7) 294 (41.5) 225 (38.7) 184 (36.7) 947 (39.1)
ART exposed‡ Yes N 27 (4.3) 10 (1.4) 7 (1.2) 5 (1.0) 49 (2.0) 0.005
Year of ART start 2014 N 161 (25.5) 208 (29.4) 160 (27.5) 161 (32.1) 690 (28.5) 0.091
2015 N 470 (74.2) 500 (70.6) 422 (72.5) 341 (67.9) 1733 (71.5)
*The P value measures heterogeneity across baseline CD4 categories. Chi-square and Kruskal–Wallis tests were used—measure heterogeneity of baseline characteristics.
†For the ﬁrst row of the table, the % refers to the % across CD4 categories. For all other rows, the % refers to the % within the CD4 category.
‡ART exposed is deﬁned as previous ART exposure of .3 months.
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individual level routine data with a waiver of informed
consent, were received from SU HREC (reference number
N12/11/074A), the Western Cape Government (Ref no.
WC_2015RP51_715), and the City of Cape Town (Ref no
10529) research committees.
RESULTS
A total of 2593 individuals started ART during the
study enrollment period. Baseline CD4 counts were
missing for 170 individuals (6.6%) who were excluded
leaving 2423 (93.4%) individuals in the analysis (Table 1).
Median follow-up time was 10.4 months (interquartile
range [IQR]: 6.4–15.6). In total, 600 (24.7%) individuals
were deﬁned LTFU with a median follow-up of 3.4 (IQR:
0.9–7.2) months among those LTFU. There were 134
(5.5%) individuals with TFO recorded during the follow-
up period.
Median baseline CD4 count was 328 cells/mL (IQR:
195–468), median age 31 years (IQR: 26–38), and 1643
(67.8%) individuals were women. The numbers of individuals
initiating ART in different baseline CD4 count categories
varied from 631 (26.0%) at CD4 0–200 cells/mL to 502
(20.7%) at CD4 .500 cells/mL (Table 1). Baseline TB was
recorded in 285 individuals (11.8% 95% CI: 10.5% to
13.1%). Baseline TB prevalence ranged from 25.7% (95%
CI: 22.3% to 29.3%) at baseline CD4 counts ,200 cells/mL
to 5.2% (95% CI: 3.4% to 7.5%) at CD4 .500 cells/mL. A
small number of individuals, 49 (2.0%), were recorded as
having previous ART exposure of more than 3 months
duration at baseline, the majority (33, 67.5%) of whom
presented with a baseline CD4 count ,200 cells/mL. More
individuals attended metro 1 (1022, 42.2%) and metro 2
clinics (947, 39.1%) compared with the rural clinic
(454, 18.7%).
TABLE 2. Incidence of TB and Characteristics of Incident TB Cases by Baseline CD4 Count
Baseline CD4
Categories (Cells/mL)
TB Incidence
Bacteriologically Conﬁrmed
TB Site of TB Disease Treatment Type
PY* TB Cases IR (95% CI) Yes No Pulmonary Extrapulmonary New TB Retreatment TB
N N TB Cases/100PY N (%) N (%) N (%) N (%) N (%) N (%)
0–200 509 49 9.62 (7.27 to 12.73) 29 (59.2) 20 (40.8) 39 (79.6) 10 (20.4) 31 (63.3) 18 (36.7)
201–350 667 21 3.15 (2.05 to 4.83) 14 (66.7) 7 (33.3) 18 (85.7) 3 (14.3) 15 (71.4) 6 (28.6)
351–500 545 21 3.85 (2.51 to 5.91) 14 (66.7) 7 (33.3) 18 (85.7) 3 (14.3) 17 (80.9) 4 (19.1)
.500 475 6 1.26 (0.57 to 2.81) 5 (83.3) 1 (16.7) 6 (100.0) 0 (0.0) 5 (83.3) 1 (16.7)
Total 2196 97 4.41 (3.62 to 5.39) 62 (63.9) 35 (36.1) 81 (83.5) 16 (16.5) 68 (70.1) 29 (29.9)
This table includes all individuals in the study sample including those with baseline TB.
*PY person time was measured from the estimated time of the end of TB treatment in individuals on TB treatment at baseline. In all other participants, person time was measured
from the date of ART start.
FIGURE 1. Kaplan–Meir failure esti-
mates for incident TB stratified by
baseline CD4 cell count categories.
BLCD4: Baseline CD4 cell count.
Log-rank test for equality of survivor
functions: P , 0.001.
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There were 97 incident TB cases during 2196 PY of
follow-up [IR: 4.41/100 PY (95% CI: 3.62 to 5.39) (Table 2)].
Eleven (11.3%) of these incident cases occurred in individ-
uals with baseline TB. Kaplan–Meier estimates showed lower
rates of incident TB in individuals with baseline CD4 counts
.500 cells/mL when compared with those with CD4 ,500
cells/mL and across all CD4 categories (P , 0.001) (Fig. 1).
TB IRs in different baseline CD4 count categories ranged
from 9.62/100 PY (95% CI: 7.27 to 12.73) at CD4 0–200
cells/mL to 1.26/100 PY (95% CI: 0.57 to 2.81) at CD4 .500
cells/mL (Table 2). There was a nonsigniﬁcant trend toward
a decrease in TB incidence at longer follow-up duration; IRs
were 5.96/100PY (95% CI: 4.24 to 8.38) from 0 to 3 months,
4.73/100PY (95% CI: 3.14 to 7.12) from 4 to 6 months, 4.73/
100PY (95% CI: 3.14 to 7.12) from 4 to 6 months, and 3.04/
100PY (95% CI: 1.79 to 5.13) from 13 to 24 months. When
analyzing TB incidence by baseline CD4 category and
follow-up duration, there were, notably, no recorded incident
TB cases during the ﬁrst 3 months of follow-up among
individuals with baseline CD4 counts .500 cells/mL. Subset
analysis excluding individuals with baseline TB showed
similar TB IRs and with IRs ranging from 6.6/100PY (95%
CI: 4.69 to 9.29) from 0 to 3 months to 2.97/100PY (95% CI:
1.72 to 5.12) from 13 to 24 months.
Of 97 incident TB cases, 81 (83.5%) cases were
pulmonary and 16 (16.5%) extrapulmonary. (Table 2).
Sixty-eight (70.1%) cases were recorded as new (not
previously treated) and 29 (39.9%) as having been pre-
viously treated but were not on TB treatment at initiation
of ART.
Sixty-two (63.9%) incident TB cases were bacteriolog-
ically conﬁrmed, most commonly on sputum using Xpert (54,
86.0%). Of the 35 (36.1%) incident TB cases not bacterio-
logically conﬁrmed, diagnosis was based on x-ray for 21
(60.0%). There were no signiﬁcant differences across baseline
CD4 count categories in the proportions of TB cases that were
pulmonary or extrapulmonary, new or retreatment cases, or
bacteriologically conﬁrmed.
TABLE 3. Cox Regression Modeling of Baseline Characteristics and Incident TB
Unadjusted Analyses Adjusted Analyses
HR
(95% CI) P
AHR
(95% CI) P
Baseline CD4* (Cells/mL)
.500 0.13 (0.06 to 0.32) ,0.001 0.15 (0.06 to 0.36) ,0.001
350–500 0.41 (0.24 to 0.68) 0.45 (0.27 to 0.77)
200–350 0.33 (0.20 to 0.56) 0.36 (0.21 to 0.60)
0–200 1.00 1.00
Gender
Male 2.58 (1.73 to 3.85) ,0.001 2.16 (1.41 to 3.30) ,0.001
Female 1.00 1.00
Clinic
Metro 1 1.00 0.212 1.00 0.047
Metro 2 1.26 (0.77 to 2.05) 1.54 (0.89 to 2.66)
Rural 1 1.63 (0.95 to 2.79) 2.17 (1.19 to 3.97)
Age category, yrs
15–25 0.84 (0.47 to 1.49) 0.465 1.18 (0.66 to 2.13) 0.951
26–35 1.00
36–45 1.38 (0.84 to 2.27) 1.28 (0.68 to 1.87)
46–55 1.34 (0.69 to 2.61) 1.22 (0.62 to 2.38)
.55 1.52 (0.47 to 4.89) 1.34 (0.41 to 4.38)
Pregnant at baseline†
Yes 0.51 (0.16 to 1.62) 0.207 0.79 (0.23 to 2.46) 0.727
Baseline TB‡
Yes 1.50 (0.80 to 2.82) 0.155 0.83 (0.41 to 1.53) 0.487
Previous ART exposure of .3 mo
Yes 3.94 (1.82 to 8.52) 0.001 3.28 (1.49 to 7.2) 0.003
Year ART start
2014 0.97 (0.62 to 1.53) 0.906 0.75 (0.45 to 1.26) 0.272
2015 1.00 1.00
All individuals were included in this analysis regardless of baseline TB status. Follow-up time is therefore not equal; time on ART as follow-up for individuals on TB treatment at
ART initiation was delayed until the estimated end of TB treatment (6 months after TB treatment initiation).
Baseline characteristics for inclusion in multivariate modeling were chosen based on clinical signiﬁcance. For baseline characteristics with more than 2 categories, likelihood ratios
were used—estimate P values for hazard of incident TB.
*Baseline CD4 count was the most recent CD4 count completed in the 6 months before ART initiation.
†All individuals initiating ART are screened for pregnancy at baseline.
‡Baseline TB was deﬁned as having started TB treatment within the 6 months before ART initiation.
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Multivariate Cox regression showed a lower hazard of
incident TB (adjusted HR [aHR] 0.27; 95% CI: 0.12 to 0.62)
among individuals with baseline CD4 count .500 cells/mL
when compared with CD4 #500 cells/mL. When stratifying
by all baseline CD4 count categories, aHR for incident TB
were as follows: aHR 0.15 (95% CI: 0.06 to 0.36) at CD4
.500 cells/mL; aHR 0.45 (95% CI: 0.27 to 0.77) at CD4 351–
500 cells/mL; and aHR 0.36 (95% CI: 0.21 to 0.60) at CD4
201–350 cells/mL compared with CD4 0–200 cells/mL (Table
3). The aHR of incident TB was higher among men (aHR
2.16; 95% CI: 1.41 to 3.30), individuals with previous ART
exposure more than 3 months (aHR 3.28; 95% CI: 1.49 to
7.2), and individuals attending the rural clinic (aHR 2.17;
95% CI: 1.19 to 3.97).
A subset analysis that excluded the 285 individuals
with baseline TB showed similar results (Table 4). Hazard of
TB remained lower at higher baseline CD4 counts; aHR =
0.13 (95% CI: 0.05 to 0.33) at CD4 .500 cells/mL; aHR =
0.42 (95% CI: 0.24 to 0.74) at CD4 351–500 cells/mL; and
aHR 0.35 (95% CI: 0.20 to 0.60) at CD4 201–350 cells/mL
compared with CD4 0–200 cells/mL. Hazard of incident TB
remained higher in men (aHR 2.31; 95% CI: 1.48 to 3.60),
individuals with previous ART exposure more than 3 months
(aHR 2.71; 95% CI: 1.08 to 6.81), and among individuals
attending the rural clinic (aHR 2.16; 95% CI: 1.13 to 4.13) on
subset analysis.
Sensitivity analysis using bacteriologically conﬁrmed
incident TB as the primary outcome showed similar results
with a lower hazard of bacteriologically conﬁrmed incident
TB in individuals starting ART at baseline CD4 counts .500
cells/mL compared with CD4 #500 cells/mL (aHR 0.35; 95%
CI: 0.14 to 0.89). Sensitivity analyses also conﬁrmed reduced
hazard of bacteriologically conﬁrmed incident TB at higher
baseline CD4 counts when comparing across all baseline CD4
count categories; aHR: 0.21 (95% CI: 0.08 to 0.57) at CD4
.500 cells/mL; aHR: 0.51 (95% CI: 0.26 to 0.98) at 350–500
cells/mL; aHR: 0.41 (95% CI: 0.22 to 0.79) at 201–350 cells/
mL compared with CD4 ,200 cells/mL.
Logistic regression analysis of the association of
baseline characteristics with an end point that combined
LTFU and TFO showed that adjusted odds ratios (aORs) of
LTFU and TFO at different baseline CD4 categories were
1.23 (95% CI: 0.95 to 1.61), 0.74 (95% CI: 0.56 to 0.96), and
1.05 (95% CI: 0.82 to 1.33) among individuals with baseline
CD4 counts .500, 351–500, and 201–350 cells/mL, respec-
tively when compared with those with baseline CD4 counts
#200 cells/mL. Other baseline characteristics associated with
combined LTFU and TFO included age 18 to 25 (aOR = 1.36;
TABLE 4. Subset Cox Regression Modeling of Baseline Characteristics and Incident TB Excluding Individuals With Baseline TB
Crude Hazard Ratio
(95% CI) P aHR (95% CI) P
Baseline CD4 (Cells/mL)
.500 0.11 (0.04 to 0.28) ,0.001 0.13 (0.05 to 0.33) ,0.001
351–500 0.37 (0.22 to 0.64) 0.42 (0.24 to 0.74)
201–350 0.32 (0.19 to 0.55) 0.35 (0.20 to 0.60)
0–200 1.0 1.0
Sex
Male 2.75 (1.8 to 4.19) ,0.001 2.31 (1.48 to 3.60) ,0.001
Female 1.0 1.0
Clinic
Metro 1 1.0 0.286 1.0 0.059
Metro 2 1.35 (0.8 to 2.26) 1.73 (0.98 to 3.07)
Rural 1 1.58 (0.88 to 2.84) 2.16 (1.13 to 4.13)
Age category, yrs
15–25 0.91 (0.5 to 1.63) 0.416 1.28 (0.7 to 2.32) 0.762
26–35 1 1
36–45 1.55 (0.92 to 2.61) 1.30 (0.77 to 2.21)
46–55 1.27 (0.61 to 2.63) 1.17 (0.56 to 2.44)
.55 0.65 (0.09 to 4.71) 0.57 (0.08 to 4.16)
Pregnant at baseline*
Yes 0.53 (0.17 to 1.69) 0.285 0.85 (0.26 to 2.77) 0.785
Previous ART exposure of .3 months
Yes 3.46 (1.4 to 8.55) 0.007 2.71 (1.08 to 6.81) 0.785
Year ART start
2014 0.93 (0.57 to 1.52) 0.780 1.36 (0.79 to 2.36) 0.271
2015 1.0 1.0
Individuals (285) with baseline TB were excluded. In this analysis, follow-up time equals time on ART. Baseline characteristics for inclusion in multivariate modeling were chosen
based on clinical signiﬁcance. For baseline characteristics with more than 2 categories, likelihood ratios were used—estimate P values for hazard of incident TB. Baseline CD4 count
was the most recent CD4 count completed in the 6 months before ART initiation.
*All individuals initiating ART are screened for pregnancy at baseline. Baseline TB was deﬁned as having started TB treatment within the 6 months before ART initiation.
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95% CI: 1.09 to 1.70) and age 46 to 55 (aOR 0.65; 95% CI:
0.46 to 0.93) compared with age 26 to 35, being treated at
metro 2 (aOR: 1.31; 95% CI: 1.05 to 1.66) compared with
metro 1 and baseline TB treatment (aOR: 1.44; 95% CI: 1.09
to 1.91). Male sex was not associated with increased LTFU
and TFO (aOR 1.11; 95% CI: 0.90 to 1.36) when compared
with female sex.
DISCUSSION
Life-long ART is now recommended for all HIV-
positive individuals regardless of CD4 count.2 In addition
to improving individual level clinical outcomes and poten-
tially reducing community HIV transmission, earlier ART
initiation has the potential to reduce population level TB
incidence.3,5 The impact of starting ART at baseline CD4
counts .500 cells/mL on subsequent TB incidence has been
demonstrated in randomized controlled trials; however, there
are very limited data from programmatic settings. This study
has demonstrated signiﬁcantly lower TB incidence for
individuals starting ART at CD4 counts .500 cells/mL
(1.26/100 PY (95% CI: 0.57 to 2.81) compared with those
starting at lower CD4 counts. This rate is, however, higher
than previously reported TB case notiﬁcation rates for the
HIV-negative population, aged 15–60 years, in the Cape
Town area (0.48/100PY).21 A direct comparison cannot be
made because these were different studies with different
methodologies, and interpretation of this comparison is
limited by the relatively small sample size of our study and
should be the subject of further evaluation.
In contrast to previous studies among HIV-positive
individuals,7,8,10 the hazard of incident TB on ART in this
study was higher among men, reasons for which are not clear
from these data. This may, however, be due to lower ART
adherence among men, with associated greater immunosup-
pression, as reported in other studies.22 There is a reported
trend toward recurrent episodes of ART nonadherence among
individuals on ART, and it is therefore possible that
individuals with previous ART exposure were more likely
to be nonadherent to ART, which may account for the higher
TB incidence in this group.23 The higher TB incidence at the
rural clinic is likely to, in part, reﬂect higher background
annual TB incidence.17 Previous studies have shown a strong
trend toward decreasing TB incidence with increasing
duration of follow-up after ART initiation.8,10 By contrast,
in this study, there was a trend toward decreased TB
incidence at longer durations of ART; however, it was not
statistically signiﬁcant. This may be in part due to limited
sample size; however, there were no recorded incident TB
cases during the ﬁrst 3 months on ART among individuals
with baseline CD4 counts starting .500 cells/mL, which
would have reduced overall cohort incidence during
early ART.
Unmasking of TB is known to contribute to TB
incidence during the ﬁrst 3 months on ART.24,25 The absence
of incident TB cases during this period of ART in HIV-
positive individuals who have not spent time pre-ART at CD4
counts lower than 500 cells/mL in this high-TB burden setting
is promising and should be the subject of future research.
Effective management of HIV and TB at PHC clinics is
critical in reducing associated morbidity and mortality in
high-burden settings.26,27 Integration of HIV and TB services
in PHC clinics is increasingly recommended,26,27 but has not
always been shown to lead to improved clinical outcomes.
The best way to integrate services may be highly context
speciﬁc,28,29 and there remains the need for high quality data
evaluating best practices for HIV and TB integration.2
Differentiated models of care, which provide intensiﬁed care
for high-risk individuals in PHC clinics, may be a successful
strategy for improving integrated HIV and TB care.30,31 To
this end, studies such as this one, which have identiﬁed key
baseline risk factors for TB incidence on ART, could be used
to develop risk matrices for incorporation into differentiated
models of care for improving clinical outcomes in HIV and
TB co-infected individuals.
The HPTN 071 (PopART) trial has provided a unique
opportunity to evaluate, under programmatic conditions,
a cohort of HIV-positive individuals routinely starting ART
at baseline CD4 counts .500 cells/mL, before ART regard-
less of CD4 count being recommended by WHO and South
African guidelines. The primary outcome of this study, TB
incidence, is a topic of great public health importance, and the
analysis of an objective primary end point was strengthened
by sensitivity analyses of microbiologically conﬁrmed TB.
Data included in this analysis were representative of the
planned study cohort with only 170 (6.6%) of eligible
individuals excluded because of missing baseline CD4 count.
The prospective health systems support provided by HPTN
071 (PopART) to the study clinics was likely to have
improved the accuracy with which TB was diagnosed and
reported in ETR.net.
There were, however, limitations that require consider-
ation. ETR.net captures only individuals starting TB treat-
ment. Individuals diagnosed with TB but not started on TB
treatment were, therefore, excluded along with individuals
starting TB treatment who were erroneously not recorded in
ETR.net. Similarly, the majority of the estimated 4%–5% of
individuals diagnosed with drug-resistant TB at the time of
TB treatment start32 were not captured in ETR.net, but into
a separate database [Electronic Drug-Resistant TB register
(EDR.net)] and were therefore excluded in this analysis. The
authors were, therefore, not able to report the contribution of
MDR to incident TB cases. The omission of MDR TB cases
in this study may have reduced the overall reported TB
incidence, but given that CD4 count has not been shown to be
associated with the risk of MDR TB versus drug susceptible
TB,33 there is no evidence that the missing MDR data
differentially affected TB incidence across different baseline
CD4 categories in this study. Despite these missing data,
baseline TB prevalence stratiﬁed by baseline CD4 count
category in this study was similar to that reported for
corresponding baseline CD4 count categories by another
South African study, from a comparable area in the Cape
Metro, in which data were limited to individuals with baseline
CD4 counts # 500 cells/mL.4
Furthermore, there was marked heterogeneity of base-
line characteristics across baseline CD4 categories, and
although we adjusted for some of these characteristics in
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the Cox regression analysis, we cannot rule out that there may
be residual confounding. There were also high rates of LTFU
(24.7%) and TFO (5.5%), which are likely to have reduced
the overall reported TB incidence. When analyzing LTFU and
TFO across baseline CD4 categories, although there was
reduced LTFU and TFO among individuals with baseline
CD4 counts of 351–500 cells/mL. However, LTFU and TFO
amongst individuals with baseline CD4 counts of .500 cells/
mL, and 201–350 cells/mL was not different from LTFU and
TFO among individuals with baseline CD4 counts #200
cells/mL, and it is therefore not evident that LTFU and TFO
differentially affected TB incidence across baseline CD4
categories. LTFU and TFO were similar with respect to other
baseline characteristics associated with TB incidence. Non-
availability of viral load data after ART initiation is a further
limitation of this study. Increased viral load after ART
initiation is associated with increased incidence of TB on
ART,8 and inclusion of these data would have assisted in
interpreting the association of key baseline characteristics
with TB incidence, such as the increased hazard of TB in men
who are also associated with decreased ART adherence and
increased risk of increased viral load on ART.22
IPT has been shown to decrease the risk of TB among
individuals starting ART.11 The nonreporting of IPT pro-
vision in this study due to missing data in ETR.net and Tier.
net is a limitation. It was not apparent whether IPT uptake in
this study differed across baseline CD4 categories and the
non-availability of IPT data may therefore have biased the
primary outcomes. Anecdotally, the use of IPT was low and
inconsistent in PHC clinics in the Western Cape at the time of
this study. IPT has been shown to be effective in reducing TB
incidence in HIV-positive individuals testing TST posi-
tive.11,34,35 The need for TST testing and concerns about
isoniazid resistance are thought to have contributed to low
uptake of IPT.36,37 The need for TST testing before IPT is
debated, and recent changes to ART guidelines, with more
individuals starting ART at higher CD4 counts, when TST
testing is more sensitive,35 should be a critical consideration
in this debate going forward.
CONCLUSIONS
The HPTN 071 (PopART) trial has provided a unique
opportunity to evaluate TB incidence in the setting of
universal offer of ART through programmatic clinic data.
This study showed a signiﬁcantly lower TB prevalence and
on ART incidence among HIV-positive individuals initiating
ART at CD4 counts .500 cells/mL, suggesting that the scale-
up of ART regardless of CD4 count has the potential to
signiﬁcantly reduce TB burden among HIV-positive individ-
uals. At the same time, scale-up of other TB prevention
strategies that target both HIV-positive and HIV-negative
individuals is urgently required to contribute substantially to
TB elimination in high-HIV prevalence settings.
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